A Study of JNJ-77242113 Following Oral Administration in Healthy Chinese Adult Participants

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

February 14, 2023

Primary Completion Date

April 7, 2023

Study Completion Date

April 12, 2023

Conditions

Healthy

Interventions

DRUG

JNJ-77242113

JNJ-77242113 will be administered orally as an immediate-release (IR) file-coated tablet.

Trial Locations (1)

Peking University Third Hospital, Beijing

All Listed Sponsors

lead

Janssen Research & Development, LLC

INDUSTRY